Cited by 1,048Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

Ray, Sandip, Britschgi, Markus, Herbert, Charles, Takeda-Uchimura, Yoshiko, Boxer, Adam, Blennow, Kaj, Friedman, Leah F, Galasko, Douglas R +17 more·2007·Nature Medicine

Abstract

A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2-6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.

Integrity signals

Registry

Crossref · 10.1038/nm1653

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recently, multiple studies have shown that reduced levels of platelet-derived growth factors (PDGFs) in plasma significantly correlate with mild cognitive impairment and have proposed PDGFs as a potential biomarker for AD.

    “Recently, multiple studies have shown that reduced levels of platelet-derived growth factors (PDGFs) in plasma significantly correlate with mild cognitive impairment and have proposed PDGFs as a potential biomarker for AD [95, 96].”
  • Ray et al. found 18 signalling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control patients with close to 90% accuracy and to identify patients with mild cognitive impairment that progressed to AD 2-6 years later.

    “Ray et al.[145] have found 18 signalling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control patients with close to 90% accuracy and to identify patients with mild cognitive impairment that progressed to AD 2–6 years later.”
  • Biological analysis of the 18 proteins points to systemic deregulation of haematopoiesis, immune responses, apoptosis and neuronal support in pre-symptomatic AD.

    “Biological analysis of the 18 proteins points to systemic deregulation of haematopoiesis, immune responses, apoptosis and neuronal support in pre-symptomatic AD [145].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., Kaye, J. A., Leszek, J., Miller, B. L., Minthon, L., Quinn, J. F., Rabinovici, G. D., Robinson, W. H., Sabbagh, M. N., So, Y. T., Sparks, D. L., Tabaton, M., Tinklenberg, J., Yesavage, J. A., Tibshirani, R., & Wyss-Coray, T.
Affiliations
  • Stanford Medicine (US)
  • Sahlgrenska University Hospital (SE)
  • University of California San Diego (US)
  • Wroclaw Medical University (PL)
  • Oregon Health & Science University (US)
  • Lund University (SE)
  • University of Genoa (IT)
Venue
Nature Medicine
Published
2007-10-14
Volume
13
Issue
11
Pages
1359-1362
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2017260345
Cited by
1,048
References
6
Citations by year
2026: 11 · 2025: 26 · 2024: 27 · 2023: 30 · 2022: 40 · 2021: 41 · 2020: 36 · 2019: 34 · 2018: 47 · 2017: 48 · 2016: 56 · 2015: 63 · 2014: 77 · 2013: 95 · 2012: 94
FWCI
51.68
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
National Institute on Aging (AG 08017, AG05131, AG20603, P50AG005131, R01AG020603, P30AG008017)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, biomarkers, mild cognitive impairment, disease progression prediction, immune response, apoptosis, blood-based diagnosis
MeSH terms
Alzheimer Disease, Cognition Disorders, Humans, Phenotype, Predictive Value of Tests, Biomarkers, Intercellular Signaling Peptides and Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review